Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Although adriamycin (ADR) exhibits high anti-tumor efficacy in vitro, its clinical use in cancer chemotherapy is limited due to its high renal toxicity. This study investigated the mechanism of ADR nephropathy and the protective effect of selenium on ADR-induced kidney damage by analyzing of the relationship between selenium and mitochondria. Rats were divided into four groups. The first group was injected with saline i.p. for 21 days, the second group received the 4 mg/kg i.p. ADR every alternate day for 8 days, the third group received the 50 μg/kg i.p. Se for 21 days, and the fourth group received the Se. ADR co-administration i.p. blood pressures were assessed, the mitochondrial membrane potential (MMP) was assessed, and the adenosine triphosphate (ATP) levels were determined. The total antioxidant (TAS) and oxidant status (TOS) in cytosol, the mitochondria of kidney cells, and plasma were measured. Mitochondrial TAS decreased and TOS increased in the ADR group compared to the Se group. ADR-treated rats showed significantly lower MMP than did the control and Se groups. MMP was significantly restored in the Se + ADR group through selenium treatment compared to the ADR group (p < 0.01). In the ADR group, a reduction in ATP content was seen compared to the control and Se groups (p < 0.01). ATP level was significantly restored through treatment with selenium in the Se + ADR group compared to the ADR group (p < 0.01). We concluded that selenium is effective in vivo against ADR-induced kidney damage via the restoration of TAS and TOS, which prevented mitochondrial damage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12011-011-9273-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.
Int J Cancer
September 2025
Medical Department, iOMEDICO, Freiburg, Germany.
Existing prognostic scores for metastatic colorectal cancer (mCRC) are based on randomized clinical trial data and focus on parameters evaluated at the start of first-line (1L) treatment. Unlike these, the modified mCRC prognostic score (mCCS) was developed using real-world data from the German tumor registry colorectal cancer (TKK) and is based on pre-1L treatment information. It predicts overall survival (OS) for patients with RAS-wild-type (WT) mCRC using five tumor characteristics identified as independent negative prognostic factors.
View Article and Find Full Text PDFExperimental Mechanism of Triptolide Delaying Glomerulosclerosis in Chronic Kidney Disease.
Arch Esp Urol
August 2025
Department of Nephrology, The Fourth Hospital of Changzhou, 231002 Changzhou, Jiangsu, China.
Objective: To explore the impact of Tripterygium wilfordii glycosides (TWG) on glomerulosclerosis within a rat model of chronic kidney disease (CKD), as well as the role of the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway in this mechanism.
Methods: Twenty-four clean Sprague-Dawley rats were divided into Sham group (n = 8), model group (n = 8) and TWG group (n = 8). Adriamycin nephropathy (ADRN) rat model was established by jugular vein injection of adriamycin (ADR).
The establishment of an expected concentration reference range for eltrombopag in the individualized treatment of pediatric immune thrombocytopenia.
Front Pharmacol
August 2025
Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Background: Differences in the clinical efficacy and adverse drug reactions (ADRs) of eltrombopag (ELT) in children with immune thrombocytopenia (ITP) may be positively correlated with the serum trough concentration of ELT. Individual pharmacokinetic variations primarily contribute to differences in ELT concentration among individuals. This study is the first to establish an expected concentration reference range for ELT in treating pediatric persistent/chronic ITP (P/CITP) across different age-groups.
View Article and Find Full Text PDFSafety of artificial intelligence-assisted optical diagnosis for leaving colorectal polyps in situ during colonoscopy (PRACTICE): a non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol
October 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Endoscopy Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Background: Guidelines recommend leaving in situ rectosigmoid polyps diagnosed during colonoscopy that are 5 mm or smaller if the endoscopist optically predicts them to be non-neoplastic. However, no randomised controlled trial has been done to examine the efficacy and safety of this strategy.
Methods: This open-label, multicentre, non-inferiority, randomised controlled trial enrolled adults age 18 years or older undergoing colonoscopy for screening, surveillance, or clinical indications across four Italian centres.
Colorectal mucosal exposure area assessment based on artificial intelligence: a multi-center, prospective, observational study.
Endoscopy
September 2025
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.
Background: This study proposed a new quality control indicator, cumulative colorectal mucosal exposure area (CCMEA) for colonoscopy to assess mucosal exposure, constructed CCMEA system based on deep learning. and validated the indicator in a multi-center prospective observational study.
Methods: The CCMEA system worked based on ResNet50 and UNet++.